{"disease":{"id":"plasma-cell-myeloma","name":"plasma cell myeloma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05334069","title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT04566328","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1450,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT01863550","title":"Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1087,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT04458831","title":"A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":583,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05405166","title":"SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":531,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT03870633","title":"Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple Myeloma","phase":"","overall_status":"COMPLETED","enrollment_count":521,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT05561387","title":"Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":510,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT03319667","title":"A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":475,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05136807","title":"Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04537871","title":"Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":350,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04270409","title":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":337,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT02990338","title":"Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":307,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT03275285","title":"Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":302,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT03314974","title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT07319897","title":"A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT03937635","title":"Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":288,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT04643002","title":"Isatuximab in Combination With Novel Agents in RRMM - Master Protocol","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":258,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT02861417","title":"Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":204,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02726750","title":"Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04090619","title":"Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":192,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05312255","title":"Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma","phase":"NA","overall_status":"RECRUITING","enrollment_count":175,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT00536601","title":"High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT01415882","title":"Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":165,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT02661035","title":"Allo HSCT Using RIC for Hematological Diseases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT03246906","title":"Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":150,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT00719888","title":"Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT03141437","title":"Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":130,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03017820","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":127,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02420860","title":"Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":113,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04354246","title":"COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":110,"lead_sponsor_name":"Compugen Ltd","has_results":false},{"nct_id":"NCT03194867","title":"Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT03858205","title":"Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT02727803","title":"Personalized NK Cell Therapy in CBT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05011045","title":"Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05053100","title":"Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03078452","title":"Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy","phase":"NA","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Emory University","has_results":true},{"nct_id":"NCT02513186","title":"Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06630806","title":"A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":87,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT01864018","title":"Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT02506959","title":"Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT06271252","title":"A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":81,"lead_sponsor_name":"OriCell Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT03012880","title":"Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT04271644","title":"BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT04776330","title":"a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT00966693","title":"Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03317899","title":"Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":true},{"nct_id":"NCT01251575","title":"Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT01372540","title":"Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT00723099","title":"Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT04782687","title":"Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":73,"lead_sponsor_name":"US Oncology Research","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}